Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.

@article{Li2011EffectivenessAC,
  title={Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.},
  author={Jie Li and Ellie S Hamilton and Louette Vaughn and Michael Graiser and Heather M Renfroe and Mary Jo Lechowicz and Amelia A. Langston and Jefferson Mark Prichard and Darlene A Anderson and Charise L. Gleason and Sagar Lonial and Christopher R Flowers and Jonathan L. Kaufman and Edmund K Waller},
  journal={Transfusion},
  year={2011},
  volume={51 10},
  pages={
          2175-82
        }
}
BACKGROUND Plerixafor is a recently Food and Drug Administration (FDA)-approved CXCR4 antagonist, which is combined with granulocyte-colony-stimulating factor (G-CSF) to facilitate stem cell mobilization of lymphoma and myeloma patients. STUDY DESIGN AND METHODS To evaluate the effectiveness and the related costs of a "just-in-time" strategy of plerixafor administration, we performed a retrospective cohort study comparing 148 consecutive lymphoma and myeloma patients in whom mobilization was… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS